PD-1抑制剂治疗广泛期小细胞肺癌患者的疗效及安全性  

Efficacy and Safety of PD-1 Inhibitors in the Treatment of Patients with Extensive-stage Small Cell Lung Cancer

作　　者：李亚伟 韩正全[1] 张竞竞[1] 苏方[1] LI Yawei;HAN Zhengquan;ZHANG Jingjing;SU Fang(Department of Oncology The First Affiliated Hospital of Bengbu Medical College,Bengbu 233004,China)

机构地区：[1]蚌埠医学院第一附属医院肿瘤内科,安徽蚌埠233004

出　　处：《中国医药指南》2023年第32期24-27,共4页Guide of China Medicine

摘　　要：目的研究PD-1抑制剂在广泛期小细胞肺癌(extensive-stage small cell lung cancer,ES-SCLC)患者一线治疗中的疗效及安全性。方法回顾性选取64例ES-SCLC患者为研究对象,分为对照组41例和试验组23例。对照组接受化疗,试验组在化疗的基础上联合PD-1抑制剂,观察两组的客观有效率、无进展生存期(PFS)、肿瘤标志物水平、不良反应发生的情况。结果试验组客观有效率82.60%,较对照组(51.22%)高(P<0.05)。试验组较对照组中位PFS明显提高(8.9个月vs.6.6个月)(P<0.05)。观察治疗4周期后两组的标志物NSE、ProGRP水平的变化,两组差别均无统计学意义(P>0.05)。试验组和对照组的3级及以上不良反应发生率分别43.47%和46.34%,差别无统计学意义(P>0.05)。结论化疗联合PD-1单抗对ES-SCLC较单纯标准化疗具有较好的临床获益和安全性。Objective To study the efficacy and safety of PD-1 inhibitors in the first-line treatment of patients with extensive-stage small cell lung cancer(ES-SCLC).Methods Sixty-four ES-SCLC patients were retrospectively selected as study subjects and divided into 41 cases in the control group and 23 cases in the experimental group.The control group received chemotherapy,and the experimental group combined PD-1 inhibitor on the basis of chemotherapy,and observed the objective effective rate,progression-free survival(PFS),tumour marker levels,and the occurrence of adverse reactions in the two groups.Results The objective effective rate of the experimental group was 82.60%,which was higher than that of the control group(51.22%)(P<0.05).The median PFS of the test group was significantly higher than that of the control group(8.9 months vs.6.6 months)(P<0.05).The changes of NSE and ProGRP in the two groups after 4 cycles of treatment were observed,and the differences between the two groups were not statistically significant(P>0.05).The incidence rates of grade 3 and above adverse reactions in the test group and control group were 43.47%and 46.34%,respectively,and the differences were not statistically significant(P>0.05).Conclusions Chemotherapy combined with PD-1 monoclonal antibody has a significant clinical benefit and manageable safety profile over standard chemotherapy alone in ES-SCLC.

关 键 词：广泛期小细胞肺癌 免疫治疗 化疗 PD-1单抗 

分 类 号：R734.2[医药卫生—肿瘤]